Chimeric antigen receptors for the retargeting of cytotoxic effector cells

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 4, 2001, Pages 523-534

  Uherek, C ^a   Groner, B ^a   Wels, W ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CHIMERA; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0034885940     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160152509136     Document Type: Article

References (76)

1. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
2. Tumor antigens recognized by T cells
3. Design and evaluation of antigen-specific vaccination strategies against cancer
4. A fresh look at tumor immunosurveillance and immunotherapy
5. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
6. Identification of human cancers deficient in antigen processing
7. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
8. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
9. Signal transduction by lymphocyte antigen receptors
10. Signal transduction by the TCR for antigen
11. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions
12. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
13. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation
14. Tumor-specific T-bodies: Towards clinical application
15. Man-made antibodies
16. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
17. New simplified molecular design for functional T cell receptor
18. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways
19. Signaling function of reconstituted CD16: Zeta:gamma receptor complex isoforms
20. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes
21. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains
22. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins
23. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
24. Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma
25. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
26. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity
27. Impact of chimeric immune receptor extracellular protein domains on T cell function
28. T cell activation by recombinant Fc epsilon RI gamma-chain immune receptors: An extracellular space domain impairs antigen-dependent T cell activation but not antigen recognition
29. + T lymphocytes armed with universal T-cell receptors
30. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor
31. Anti-tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions
32. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL
33. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
34. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells
35. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor
36. A novel strategy in the elimination of disseminated melanoma cells: Chimeric receptors endow T cells with tumor specificity
37. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera
38. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30
39. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: Implications for cellular immunotherapy of CD20+ malignancy
40. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors
41. Neu and its ligands: From an oncogene to neural factors
42. New EMBO Members' Review: The ErbB signaling network: Receptor heterodimerization in development and cancer
43. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor
44. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor
45. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
46. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery
47. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes
48. Cytotoxic T lymphocytes with a grafted recognition specificity for erbB2-expressing tumor cells
49. Biotechnological and gene therapeutic strategies in cancer treatment
50. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
51. Stable expression of the ecotropic retrovirus receptor in amphotropic packaging cells facilitates the transfer of recombinant vectors and enhances the yield of retroviral particles
52. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production
53. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies
54. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
55. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes
56. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
57. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors
58. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes
59. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
60. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation
61. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: Optimal design for T cell activation
62. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120
63. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells
64. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
65. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
66. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells
67. Retroviral vector-mediated gene expression in hematopoietic cells
68. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
69. The graft-versus-leukemia effect
70. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors
71. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors
72. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
73. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen
74. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
75. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules
76. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen